Quote · TED Talks Daily
Can Ozempic end addiction? | Dhruv Khullar | Your Body on Tech
Where this was said
Dhruv Khullar's TED Talk: GLP-1s and the Science of Addiction
At 9:48 · chapter starts 5:29
The centerpiece of the episode, Khullar's TED Talk opens with Mary — a patient who had failed rehab, AA, and Antabuse before enrolling in an Ozempic clinical trial and achieving sobriety [1] — Dhruv Khullar "Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the cravin…" 05:29 . From there, Khullar unfolds the drug's origin story: discovered in the 1980s but unworkable until a Gila monster researcher found a peptide in lizard venom that lasted hours rather than minutes. That discovery unlocked a class of drugs now showing effects far beyond digestion — specifically in the brain's mesolimbic reward pathway. GLP-1s appear to blunt dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. One neuroscientist told Khullar this suggests addiction may have a single universal pathology. But Khullar urges caution: these 'moderation molecules' can become desire dampeners, and anhedonia is a real risk. He closes by invoking Aristotle — and then dismantling him: Aristotle never faced Doritos, TikTok, or fentanyl. Moderation today isn't just a virtue; it is, the science suggests, a physiological state [2] — Dhruv Khullar "GLP-1s suggest that Aristotle's moderation, it's not just a virtue, it is a physiological state. It isn't just about character, it is about…" 14:44 .
Mary had tried rehab, AA, and Antabuse — and failed every time. Then she enrolled in a clinical trial for Ozempic. Within weeks, the craving was gone. She stopped drinking, lost 55 pounds, ended a bad relationship, and started exercising. GLP-1s didn't just treat her addiction; they gave her room to rebuild her life.
GLP-1 was discovered in the 1980s, but it broke down in minutes — useless as a drug. The breakthrough came from an unexpected place: Gila monster venom, which contained a similar peptide that could persist for hours. That discovery launched one of the most consequential drug classes in modern medicine.
GLP-1 (glucagon-like peptide 1) was first discovered in the 1980s and initially studied for diabetes management.
A scientist studying Gila monsters discovered the lizard's venom contained a GLP-1-like peptide that could persist for hours, catalyzing the GLP-1 drug revolution.
GLP-1s don't just reduce appetite — they appear to dampen dopamine spikes across every major addiction: alcohol, cocaine, nicotine, gambling, even social media. A neuroscientist told Khullar this suggests addiction has a single universal pathology, and GLP-1s may be part of how we fix it.
GLP-1s blunt the dopamine spikes triggered by cocaine, alcohol, and other addictive substances — but they don't drain dopamine entirely. Mice given GLP-1s and cocaine had smaller dopamine surges but maintained baseline neurotransmitter levels. The drugs moderate without eliminating the will to live.
